Company Filing History:
Years Active: 2012
Title: Yo Tabuse: Innovator in Hepatocellular Carcinoma Detection
Introduction
Yo Tabuse is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the detection of hepatocellular carcinoma, a common type of liver cancer. His innovative work has the potential to improve early detection and treatment outcomes for patients.
Latest Patents
Yo Tabuse holds a patent for a hepatocellular carcinoma protein marker. This patent describes a method of assessing hepatocellular carcinoma by utilizing a protein that exhibits a different phosphorylated state in hepatocellular carcinoma cells compared to non-hepatocellular carcinoma cells. The hepatocellular carcinoma protein marker includes tumor rejection antigen gp96, which is formed of the amino acid represented by SEQ ID NO: 1. This marker is measured for its phosphorylated state to detect the presence or absence of hepatocellular carcinoma.
Career Highlights
Throughout his career, Yo Tabuse has been associated with NEC Corporation, where he has worked alongside notable colleagues such as Hirotaka Minagawa and Kenji Miyazaki. His work at NEC Corporation has allowed him to collaborate with other experts in the field, further enhancing his contributions to medical research and innovation.
Collaborations
Due to space constraints, the details of collaborations will not be included.
Conclusion
Yo Tabuse's innovative work in the detection of hepatocellular carcinoma through protein markers represents a significant advancement in medical diagnostics. His contributions have the potential to greatly impact patient care and treatment strategies in the fight against liver cancer.